Waycross Partners’s Bristol-Myers Squibb BMY Stock Holding History

Waycross Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Hold	4,557	–	–	0.02%	69
2026 Q1	$276K	Hold	4,557	–	–	0.03%	66
2025 Q4	$246K	Hold	4,557	–	–	0.02%	92
2025 Q3	$206K	Hold	4,557	–	–	0.02%	94
2025 Q2	$211K	Hold	4,557	–	–	0.02%	92
2025 Q1	$278K	Hold	4,557	–	–	0.03%	61
2024 Q4	$258K	Hold	4,557	–	–	0.03%	61
2024 Q3	$236K	Buy	+4,557	New	+$214K	0.03%	65
2024 Q2	–	Sell	-4,557	Closed	-$247K	–	73
2024 Q1	$247K	Hold	4,557	–	–	0.04%	68
2023 Q4	$234K	Hold	4,557	–	–	0.04%	80
2023 Q3	$264K	Hold	4,557	–	–	0.06%	88
2023 Q2	$291K	Hold	4,557	–	–	0.06%	91
2023 Q1	$316K	Hold	4,557	–	–	0.09%	81
2022 Q4	$328K	Hold	4,557	–	–	0.12%	79
2022 Q3	$324K	Hold	4,557	–	–	0.22%	84
2022 Q2	$351K	Hold	4,557	–	–	0.23%	74
2022 Q1	$333K	Hold	4,557	–	–	0.19%	77
2021 Q4	$284K	Hold	4,557	–	–	0.16%	84
2021 Q3	$270K	Hold	4,557	–	–	0.17%	87
2021 Q2	$304K	Hold	4,557	–	–	0.16%	72
2021 Q1	$288K	Hold	4,557	–	–	0.16%	82
2020 Q4	$283K	Buy	+4,557	New	+$280K	0.18%	74

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Waycross Partners's BMY Position: Q2 2026 in Review

Waycross Partners held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 4,557 shares worth $263K. The position accounts for 0.02% of the portfolio, ranked #69.

Waycross Partners first reported a position in BMY in Q4 2020 and has held it in 22 quarters since. The position peaked at $351K in Q2 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Waycross Partners held 4,557 shares of Bristol-Myers Squibb worth $263K as of Q2 2026.
Waycross Partners left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.02% of Waycross Partners's portfolio in Q2 2026, its #69 holding.
Waycross Partners first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 22 quarters since.
Waycross Partners's Bristol-Myers Squibb position peaked at $351K in Q2 2022.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Waycross Partners's 13F filing for Q2 2026, filed 11 Aug 2026.